BioSpace News Archive

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced financial results for the three and nine months ended September 30, 2022, and provided a business update.

Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Humacyte, Inc. announced financial results for the third quarter ended September 30, 2022, and highlighted recent corporate accomplishments.

Clearside Biomedical, Inc. announced that George Lasezkay, Pharm.D., J.D., Clearside’s President and Chief Executive Officer and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will participate in a Fireside Chat at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022, from 8:35 - 9:05 a.m. Eastern Time, in New York, NY.

Sobi North America announced that the U.S. FDA issued an emergency use authorization for KINERET® for the treatment of COVID-19 in adult patients who are hospitalized with positive results of direct SARS-CoV-2 viral testing with pneumonia, requiring supplemental oxygen, and are at risk of progressing to severe respiratory failure, and are likely to have an increased blood level of a certain suPAR that may be a sign of increased risk of worsening of the disease.

Theriva Biologics announced that it plans to host a conference call on Friday, November 11, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide a corporate update.

BioXcel Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2022 and provided an update on key strategic initiatives.

GH Research PLC reported financial results for the third quarter ended September 30, 2022 and gave updates on its business.

Daré Bioscience, Inc., a leader in women’s health innovation, reported financial results for the quarter ended September 30, 2022 and provided a company update.

Asieris Pharmaceuticals announced that the U.S. Food and Drug Administration has approved the Investigational New Drug application for its oral drug APL-1401 for the treatment of moderately-to-severely active ulcerative colitis.